(Boursier.com) — The biotechnology company Cellectis announced the publication of an abstract accepted for presentation at the European Hematology Association (EHA) Hybrid Congress, to be held June 8-15, 2023 in Frankfurt.
Cellectis will present a poster on updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
“Cellectis is proud to present updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. These data are very encouraging for patients whose options therapies are limited to non-existent, particularly for those who have failed CD19 antigen-directed CAR T therapy and allogeneic stem cell transplantation,” said Mark Frattini, MD, Ph.D., Medical Director of Cellectis.
©2023 Boursier.com